ELIAS Animal Health Hires New Exec, Seeking $10M for Cancer Treatment

ELIAS Animal Health has hired Brian Segebrecht chief revenue officer and prepared to raise funds for a new first-in-class dog treatment. Photo credit: Shutterstock (SeventyFour)

Posted April 17, 2024

Olathe-based ELIAS Animal Health announced it has appointed a new chief revenue officer ahead of the company’s plan to raise $10 million for a new treatment of bone cancer in dogs.

ELIAS, a cancer therapeutics company for companion animals, appointed Brian Segebrecht as CRO, according to a release. Segebrecht will lead the commercialization of the company’s ELIAS Cancer Immunotherapy (ECI), a first-in-class adoptive cell therapy that treats osteosarcoma in canines.

ELIAS is planning on pursuing a $10 million Series A capital raise that would help fund the manufacturing and commercial launch of ECI. The capital raise will also fund the company’s future product pipeline

Most recently, Segebrecht served as CEO of Sentrx Animal Care Inc. for more than six years. Before that, he also worked for six years at Shawnee-based Bayer Animal Health.

“His leadership at ELIAS will be critical as we continue to pursue funding to support the commercialization of our lead product, as well as the continued expansion of our portfolio of companion animal cancer therapeutics,” ELIAS CEO, Tammie Wahaus said.

ELIAS is seeking regulatory approval for ECI by Q4 2024, Wahaus said in the release.